ReviewDrugs2007
Ampicillin/sulbactam: current status in severe bacterial infections.
Review in Drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Global Epidemiology and Antimicrobial Resistance of Metallo-β-Lactamase (MBL)-Producing Acinetobacter Clinical Isolates: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesPooled it
- KEGG orthology-based machine learning reveals functional determinants of antimicrobial resistance inMicrobiology spectrum · 2026Article
- Ampicillin Is a Substrate of Organic Anion Transporters 3.Biopharmaceutics & drug disposition · 2026Article
- Transforming Fragile Hydrogel Chips Into Standardized Cartridges via Contact Line Pinning for Robust Microfluidics.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Postoperative outcomes following institutional antibiotic protocol changes in complicated pediatric appendicitis.World journal of pediatric surgery · 2026Article
- Article
- Concealed Peritonitis Due to Stomach Perforation from a Fish Otolith: A Case Report.Reports (MDPI) · 2025Article
- MALDI-TOF MS Biomarkers for Methicillin-ResistantMetabolites · 2025Review
- Development and Validation of a High-Performance Liquid Chromatography-Ultraviolet Spectrometry Method for Ampicillin and Its Application in Routine Therapeutic Drug Monitoring of Intensive Care Patients.Therapeutic drug monitoring · 2025Article
- Impact of Hypothermic Temperature Control on Plasma and Soft Tissue Pharmacokinetics of Penicillin/Beta-Lactamase Inhibitor Combinations in Patients Resuscitated After Cardiac Arrest.Clinical pharmacokinetics · 2025Article
- Spatial population dynamics of bacterial colonies with social antibiotic resistance.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Priestia megaterium cells are primed for surviving lethal doses of antibiotics and chemical stress.Communications biology · 2025Article
- Sulbactam-Durlobactam: A Novel Antibiotic Combination for the Treatment ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Review
- Development of a luciferase-based Gram-positive bacterial reporter system for the characterization of antimicrobial agents.Applied and environmental microbiology · 2024Article
- Screening and Selection of Antibiotics for Enhanced Production of Astaxanthin byLife (Basel, Switzerland) · 2024Article
- Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance.Nature communications · 2024Article
- Egg white hydrolysate peptides act as antimicrobial and anti-inflammatory agents for acne.Heliyon · 2024Article
- Gram-positive bacteria are primed for surviving lethal doses of antibiotics and chemical stress.bioRxiv : the preprint server for biology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ampicillin/sulbactam is a beta-lactam/beta-lactamase inhibitor combination with a broad spectrum of antibacterial activity against Gram-positive, Gram-negative and anaerobic bacteria. Data from comparative studies justify the use of ampicillin/sulbactam in a 2 : 1 ratio in various severe bacterial infections. In comparative clinical trials, ampicillin/sulbactam has proved to be a significant drug in the therapeutic armamentarium for lower respiratory tract infections and aspiration pneumonia, gynaecological/obstetrical infections, intra-abdominal infections, paediatric infections such as acute epiglottitis and periorbital cellulitis, diabetic foot infections, and skin and soft tissue infections. Of particular interest during this era of increasing antimicrobial resistance in various settings and populations is the effectiveness of sulbactam against a considerable proportion of infections due to Acinetobacter baumannii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.